27 April 2021>: Articles
A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Rare disease
Kensaku Takatsuki A , Toyoshi Yanagihara A* , Ayaka Egashira E , Naruhiko Ogo E , Seiji Yoshizawa D , Syunya Sunami D , Tatsuma Asoh D , Takashige Maeyama ADOI: 10.12659/AJCR.930286
Am J Case Rep 2021; 22:e930286
Figure 2. The clinical course of the case. CK – creatine kinase; CRP – C-reactive protein; IVIg – intravenous immunoglobulin; LVFX – levofloxacin; mPSL – methylprednisolone; PSL – prednisolone.